J. Siegel

发表

A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140).

J. Nemunaitis, S. Novello, D. Fennell, 2016 .

OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma

K. Nackaerts, S. Novello, G. Ceresoli, 2017 .

Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma

O. Hamid, J. Weber, D. Minor, 2008 .

Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide

S. Chasalow, Z. Tsuchihashi, S. Galbraith, 2008 .

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Fraser Cummings, S. Vermeire, E. Savarino, 2022, The Lancet.

Effects of Oxaliplatin, Carboplatin, and Cisplatin Across Treatment on High-Frequency Objective and Subjective Auditory Measures in Adults

J. Siegel, E. Reid, L. Dreisbach, 2017 .

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

S. Targan, S. Chasalow, Hanlin L. Wang, 2010, Cancer immunity.

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial

S. O’Day, J. Weber, D. Minor, 2011, Melanoma research.

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

A. Maraveyas, S. O’Day, O. Hamid, 2009, Clinical Cancer Research.

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

C. Higano, D. Petrylak, O. Sartor, 2021, ESMO open.

A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study

G. Kimura, S. Kinuya, Motonobu Nakamura, 2019, International Journal of Clinical Oncology.

Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials.

H. Pehamberger, J. Wolchok, K. Harmankaya, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)

C. Cleeland, T. Mendoza, C. Elbi, 2019, Journal of Patient-Reported Outcomes.

Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma: Retrospective Analysis of Efficacy and Safety Data from a Phase II Trial

O. Hamid, J. Weber, D. Minor, 2012, Journal of immunotherapy.

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

D. Gerding, Wayne N. Campbell, J. Zenilman, 2017, The Lancet. Infectious diseases.

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

B. Monk, L. Kasten, A. Schlicker, 2022, International Journal of Gynecological Cancer.

Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

T. Lynch, I. Bondarenko, F. Barlesi, 2010 .